TransMedics Group (TMDX) Competitors

TransMedics Group (NASDAQ:TMDX) and Glaukos (NYSE:GKOS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, community ranking, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Which has more volatility and risk, TMDX or GKOS?

TransMedics Group has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Which has higher earnings and valuation, TMDX or GKOS?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$401.09M	6.02	-$25.03M	$0.94	76.54
Glaukos	$314.71M	22.08	-$134.66M	-$3.02	-41.73

Does the media favor TMDX or GKOS?

In the previous week, TransMedics Group had 23 more articles in the media than Glaukos. MarketBeat recorded 46 mentions for TransMedics Group and 23 mentions for Glaukos. Glaukos' average media sentiment score of 0.29 beat TransMedics Group's score of 0.14 indicating that Glaukos is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	5 Very Positive mention(s)	7 Positive mention(s)	31 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Glaukos	5 Very Positive mention(s)	1 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate TMDX or GKOS?

TransMedics Group presently has a consensus price target of $122.70, indicating a potential upside of 70.54%. Glaukos has a consensus price target of $163.25, indicating a potential upside of 29.53%. Given TransMedics Group's higher possible upside, equities analysts clearly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Glaukos	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Do insiders & institutionals have more ownership in TMDX or GKOS?

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 99.0% of Glaukos shares are owned by institutional investors. 7.0% of TransMedics Group shares are owned by insiders. Comparatively, 6.4% of Glaukos shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Is TMDX or GKOS more profitable?

TransMedics Group has a net margin of 8.14% compared to Glaukos' net margin of -42.43%. TransMedics Group's return on equity of 18.74% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	8.14%	18.74%	4.39%
Glaukos	-42.43%	-18.99%	-11.47%

Does the MarketBeat Community prefer TMDX or GKOS?

Glaukos received 339 more outperform votes than TransMedics Group when rated by MarketBeat users. Likewise, 65.03% of users gave Glaukos an outperform vote while only 59.04% of users gave TransMedics Group an outperform vote.

Company	Underperform	Outperform
TransMedics Group	Outperform Votes 111 59.04%	Underperform Votes 77 40.96%
Glaukos	Outperform Votes 450 65.03%	Underperform Votes 242 34.97%

Summary

TransMedics Group beats Glaukos on 12 of the 18 factors compared between the two stocks.